According to filings with the U.S. Securities and Exchange Commission, Auxilus is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Adam Weisman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Auxilus
Auxilius is a data-driven, clinical trial financial management platform. We help Biotechs take control over trial costs, manage financial risk, and optimize spend in pursuit of trial targets. Its time to make financial management part of the cure. Biotechs are the driving force behind new therapies that will cure disease and transform quality of life – but a third of clinical trials fail for reasons unrelated to efficacy or safety. We started Auxilius after hundreds of conversations with experienced Chief Science Officers and CFOs who learned the hard way that clinical R&D is about more than science. Often overnight, science-led organizations become full-fledged businesses — with outsourced vendors, large budgets, operational complexity, and evolving capital needs. And yet it’s common to ignore financial maturity in pursuit of milestones. We believe that Biotechs can bring drugs to market quickly and cost effectively. We believe that small and mid-sized Sponsors really can have it all — it just takes the right tools. That’s why we’re here.

To learn more about Auxilus, visit http://www.auxili.us/

Contact:
Adam Weisman, Chief Executive Officer
617-767-3376
https://www.linkedin.com/in/weis/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.